The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2024

Filed:

Feb. 26, 2021
Applicant:

Aligos Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Leonid Beigelman, San Francisco, CA (US);

Megan Elizabeth Fitzgerald, San Francisco, CA (US);

Saul Martinez Montero, San Francisco, CA (US);

Aneerban Bhattacharya, San Mateo, CA (US);

Assignee:

Aligos Therapeutics, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1138 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01);
Abstract

The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.


Find Patent Forward Citations

Loading…